FIELD: medicine.
SUBSTANCE: invention relates to oncology and can be used in treating T-cell lymphomas expressing KIR3DL2. What is presented is using an antibody which binds the KIR3DL2 polypeptide in a combination with gemcitabine and oxaliplatin for treating T-cell lymphoma (TCL) expressing KIR3DL2. Antibody contains a VH domain with the sequence SEQ ID NO: 49 and VL domain with sequence SEQ ID NO: 44. Also disclosed is a kit containing a pharmaceutical composition containing an anti-KIR3DL2 antibody, a pharmaceutical composition containing oxaliplatin, and a pharmaceutical composition containing gemcitabine.
EFFECT: inventions provide effective treatment of peripheral TCL, adult T-cell leukaemia, TCL associated with enteropathy, or anaplastic large cell lymphoma.
11 cl, 3 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| MODIFIED CONSTANT REGION OF ANTIBODY | 2023 |
|
RU2837820C2 |
| ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
| ANTIBODY AGAINST CD147 | 2018 |
|
RU2785293C2 |
| MOLECULES TARGETING A TYPE III SECRETION SYSTEM | 2016 |
|
RU2759949C2 |
| BISPECIFIC ANTIBODY | 2021 |
|
RU2840407C1 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| MODIFIED ANTIBODY CONSTANT REGION | 2021 |
|
RU2797273C2 |
| METHODS OF COMBINED TREATMENT OF MALIGNANT NEOPLASMS, INCLUDING AGENTS BLOCKING CTLA-4 AND PD-1 | 2020 |
|
RU2833523C2 |
| IMPROVED ANTI-FLT3 ANTIGEN-BINDING PROTEINS | 2019 |
|
RU2830982C2 |
